The upcoming report from McKesson (MCK) is expected to reveal quarterly earnings of $9.44 per share, indicating an increase of 14.3% compared to the year-ago period. Analysts forecast revenues of $104.39 billion, representing an increase of 6.7% year over year.

The consensus EPS estimate for the quarter has been revised 0.2% higher over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.

Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.

While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights.

Given this perspective, it's time to examine the average forecasts of specific McKesson metrics that are routinely monitored and predicted by Wall Street analysts.

Analysts expect 'Revenue- North American Pharmaceutical' to come in at $86.53 billion. The estimate indicates a change of -3.8% from the prior-year quarter.

It is projected by analysts that the 'Revenue- Prescription Technology Solutions' will reach $1.50 billion. The estimate points to a change of +4.5% from the year-ago quarter.

Based on the collective assessment of analysts, 'Revenue- Medical-Surgical Solutions' should arrive at $2.79 billion. The estimate suggests a change of +3.3% year over year.

Analysts' assessment points toward 'Adjusted Operating Profit- North American Pharmaceutical' reaching $806.45 million. Compared to the current estimate, the company reported $950.00 million in the same quarter of the previous year.

The average prediction of analysts places 'Adjusted Operating Profit- Medical-Surgical Solutions' at $241.06 million. Compared to the present estimate, the company reported $244.00 million in the same quarter last year.

The combined assessment of analysts suggests that 'Adjusted Operating Profit- Prescription Technology Solutions' will likely reach $302.62 million. The estimate compares to the year-ago value of $269.00 million.

View all Key Company Metrics for McKesson here>>>

Shares of McKesson have experienced a change of +10.1% in the past month compared to the -0.5% move of the Zacks S&P 500 composite. With a Zacks Rank #2 (Buy), MCK is expected to outperform the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .

Zacks' Research Chief Names "Stock Most Likely to Double"

Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.

This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.

Free: See Our Top Stock And 4 Runners Up

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

 

McKesson Corporation (MCK): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research